Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Athersys initiated with a Buy at Needham; tgt $7 — Potentially transformative treatment for stroke (1.16)Needham initiates ATHX with a Buy and price target of $7. Athersys is developing MultiStem, an off-the-shelf cell therapy that promotes tissue repair. The lead indication is ischemic stroke. Existing stroke treatments, which focus on removing the offending blood clot, can only be used in a short window of time, but MultiStem has shown efficacy in a longer time window (24-36 hours) and can thus address far more patients. Athersys' Japanese partner Healios will start a 220-patient pivotal trial shortly. Data is expected in mid-2018. <strong>While there is some controversy around the Phase II data, firm believes the trial has a favorable risk:reward in what they see as a blockbuster opportunity.</strong></td> </tr></table>"